Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.15 USD | -0.35% | +0.45% | -6.02% |
03:38pm | QIAGEN NV : Berenberg reaffirms its Buy rating | ZD |
03:32pm | QIAGEN : A decent start to 2024; guidance unchanged |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 23.85 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.02% | 9.36B | A | ||
+0.44% | 42.86B | B | ||
+12.34% | 42.74B | B- | ||
+44.30% | 41.36B | A | ||
-6.20% | 27.68B | C | ||
+5.83% | 25.15B | B- | ||
-23.42% | 18.63B | B | ||
+28.22% | 12.37B | C+ | ||
-3.64% | 11.92B | C+ | ||
+6.69% | 11.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QGEN Stock
- Ratings Qiagen N.V.